Supplementary material from Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

Abstract

<p>Supplementary methods. Supplementary Table S1. Verification of the analytical sensitivity (lower limit of detection) of the KRASG12/G13 mutation-enrichment NGS assay. Supplementary Table S2. KRASG12/G13 mutations in archival tumor tissue, urine cell-free DNA (cfDNA) and plasma cfDNA. Supplementary Table S3. Systemic therapies in patients with serial urine and/or plasma cell-free DNA (cfDNA) collection. Supplementary Figure S1. Workflow and characteristics of the platform used to analyze cell-free DNA in urine and plasma. Supplementary Figure S2. Schematic of the mutation-enrichment next-generatin sequencing (NGS) assay for the detection of KRASG12/13 mutations in cell-free DNA (cfDNA). Supplementary Figure S2. Schematic of the mutation-enrichment next-generatin sequencing (NGS) assay for the detection of KRASG12/13 mutations in cell-free DNA (cfDNA). Supplementary Figure S3. Kaplan-Meier curves of overall survival (OS) based on the number of KRASG12/13 copies in cell-free DNA (cfDNA). Supplementary Figure S4. Kaplan-Meier curves of overall survival (OS) based on the concentration of cell-free DNA (cfDNA).</p>